Preclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in glioblastoma.

ABSTRACT:

Background

Glioblastoma (GBM), is the most fatal form of brain cancer, with a high tendency for recurrence despite combined treatments including surgery, radiotherapy, and chemotherapy with temozolomide. The C-X-C chemokine receptor 4 (CXCR4) plays an important role in tumour radioresistance and recurrence, and is considered as an interesting GBM target. TRT holds untapped potential for GBM treatment, with CXCR4-TRT being a promising strategy for recurrent GBM treatment. Our study focuses on the preclinical assessment of different ¹⁷⁷Lu-labelled CXCR4-targeting peptides, CTCE-9908, DV1-K-DV3, and POL3026 for GBM treatment and exploring some of the radiobiological mechanisms underlying these therapies.

Results

All three DOTA-conjugated peptides could be radiolabell

SUBMITTER: Waked A 

PROVIDER: S-EPMC11250742 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature